VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir (DTG)
Drug: Lamivudine (3TC)
Drug: Rilpivirine (RPV)

First Posted Date: 2019-07-15

Last Posted Date: 2023-11-13

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 1

Registration Number: NCT04019873

Locations: 🇪🇸
GSK Investigational Site, Barcelona, Spain

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: CAB LA+RPV LA

First Posted Date: 2019-06-28

Last Posted Date: 2023-04-14

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 115

Registration Number: NCT04001803

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254
Drug: Portia

First Posted Date: 2019-06-13

Last Posted Date: 2020-08-27

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 23

Registration Number: NCT03984825

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet

First Posted Date: 2019-06-13

Last Posted Date: 2020-07-14

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT03984838

Locations: 🇺🇸
GSK Investigational Site, Glendale, California, United States

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

Phase 1

Terminated

Conditions: HIV Infections

Interventions: Drug: GSK3732394
Drug: Placebo

First Posted Date: 2019-06-13

Last Posted Date: 2021-10-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 24

Registration Number: NCT03984812

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir + Lamivudine FDC

First Posted Date: 2019-05-10

Last Posted Date: 2021-10-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 131

Registration Number: NCT03945981

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

Dolutegravir Pediatric Liquid Formulation Study

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Dolutegravir dispersible tablet
Drug: Dolutegravir oral suspension
Drug: Dolutegravir oral solution

First Posted Date: 2019-04-19

Last Posted Date: 2020-07-31

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 22

Registration Number: NCT03921723

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir alafenamide/emtricitabine
Drug: GSK3640254

First Posted Date: 2019-02-11

Last Posted Date: 2020-04-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT03836729

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254
Drug: DTG

First Posted Date: 2019-01-25

Last Posted Date: 2020-03-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 16

Registration Number: NCT03816696

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254
Drug: Placebo matching GSK3640254 Mesylate salt

First Posted Date: 2018-12-21

Last Posted Date: 2021-02-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 34

Registration Number: NCT03784079

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy